https://scholars.lib.ntu.edu.tw/handle/123456789/480254
標題: | Recent advances and challenges in the treatment of invasive fungal infections | 作者: | PEI-LAN SHAO LI-MIN HUANG PO-REN HSUEH |
公開日期: | 2007 | 卷: | 30 | 期: | 6 | 起(迄)頁: | 487-495 | 來源出版物: | International Journal of Antimicrobial Agents | 摘要: | The frequency of invasive fungal infections (IFIs) has increased over the last decade with the rise in at-risk populations of patients. The morbidity and mortality of IFIs are high and management of these conditions is a great challenge. With the widespread adoption of antifungal prophylaxis, the epidemiology of invasive fungal pathogens has changed. Non-albicans Candida, non-fumigatus Aspergillus and moulds other than Aspergillus have become increasingly recognised causes of invasive diseases. These emerging fungi are characterised by resistance or lower susceptibility to standard antifungal agents. Invasive infections due to these previously rare fungi are therefore more difficult to treat. Recently developed antifungal agents provide the potential to improve management options and therapeutic outcomes of these infections. The availability of more potent and less toxic antifungal agents, such as second-generation triazoles and echinocandins, has led to considerable improvement in the treatment of IFIs. This article reviews the changing spectrum of invasive mycosis, the properties of recently developed antifungal agents and their role in the management of these infections. ? 2007 Elsevier B.V. and the International Society of Chemotherapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/480254 | ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2007.07.019 | SDG/關鍵字: | amphotericin B; amphotericin B deoxycholate; anidulafungin; antifungal agent; astemizole; barbituric acid derivative; carbamazepine; caspofungin; cimetidine; cisapride; cyclosporin; echinocandin; ergot alkaloid; fluconazole; indinavir; itraconazole; micafungin; phenytoin; posaconazole; quinidine; rapamycin; rifabutin; rifampicin; ritonavir; tacrolimus; terfenadine; voriconazole; warfarin; Absidia; aspergillosis; Aspergillus flavus; Aspergillus fumigatus; Aspergillus niger; Aspergillus terreus; Candida albicans; Candida glabrata; Candida krusei; Candida parapsilosis; Candida tropicalis; candidiasis; clinical protocol; clinical trial; Cunninghamella; drug bioavailability; drug metabolism; Fusarium; human; liver toxicity; mucormycosis; mycosis; priority journal; Rhizomucor; Rhizopus; short survey; Zygomycetes; Antifungal Agents; Aspergillus; Candida; Double-Blind Method; Echinocandins; Fungemia; Fungi; Humans; Mycoses; Randomized Controlled Trials as Topic; Triazoles |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。